Transaction Overview - Nord New Materials Co., Ltd. will sell 70% equity of its wholly-owned subsidiary Jiangsu Lianxin Electronics Industry Co., Ltd. to Jiangsu Jidao New Materials Technology Co., Ltd. for a transaction price of RMB 70 million [1][4] - The profit generated from this transaction is expected to account for over 10% of the company's audited net profit for the most recent fiscal year [1] - This transaction does not constitute a related party transaction or a major asset restructuring [1][6] Financial Information - As of December 31, 2024, the total assets of Jiangsu Lianxin were RMB 196.49 million, with total liabilities of RMB 117.02 million, resulting in net assets of RMB 79.47 million [5] - The revenue for the year ending December 31, 2024, was RMB 175.93 million, while the net profit was a loss of RMB 32.43 million [5] - As of March 31, 2025, the total assets were RMB 189.03 million, with total liabilities of RMB 115.61 million, leading to net assets of RMB 73.42 million [5] Transaction Details - The agreement stipulates that the buyer, Jiangsu Jidao, will pay 10% of the transfer price within three days after the agreement takes effect, and the remaining amount will be settled within three working days after the transfer [6] - The transfer of management responsibilities will occur post-payment, with Jiangsu Jidao assuming operational control of Jiangsu Lianxin [6][7] - The transaction is structured to ensure that Jiangsu Lianxin will not incur any additional liabilities beyond those confirmed in the agreement [7] Impact on the Company - The sale is aimed at resource integration and optimizing the asset structure, aligning with the company's current business development needs [7] - The transaction is not expected to affect the company's normal production and operational activities, nor will it harm the interests of the company and its shareholders [7][8] - There will be no changes in management or personnel arrangements as a result of this transaction [7]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 近日，步长医学诊断与有关各方正式签署了《减资协议》。协议主要内容如下： 上述全部协议主体合称"各方"，单称"一方"；乙方各方合称"乙方"。 （二）本次减资 1、各方同意，本次减资完成后，步长医学诊断的注册资本将由5,882.3529万元减少至1,186.8245万元 2、各方同意，由于本次减资涉及的出资额为乙方认缴但尚未实缴的部分，不涉及向乙方退回出资，本 次减资对价为0元。 3、本次减资完成后，步长医学诊断的股权结构变更为： 一、交易概述 2024年11月27日，山东步长制药股份有限公司（以下简称"公司"或"步长制药"）召开第五届董事会第九 次会议，审议通过了《关于控股子公司减少注册资本暨关联交易的议案》，同意公司控股子公司步长 （广州）医学诊断技术有限公司（以下简称"步长医学诊断"）全体股东（包括公司、公司关联人及其他 股东）对步长医学诊断进行减资。本次减资完成后，步长医学诊断的注册资本将由5,882.3529万元减少 至1,186.8245万元。具体内容详见公司2024年1 ...

一、关于转让全资子公司股权及债权的概述 福州达华智能科技股份有限公司（以下简称"公司"）于 2025 年 4 月 18 日 召开第五届董事会第五次会议，会议审议通过了《关于转让全资子公司股权及债 权的议案》，根据公司战略发展的需要，为进一步有效整合资源，增强公司的持 续经营能力，结合目前公司的产业链布局，公司将全资子公司北京慧通九方科技 有限公司（以下简称"北京慧通"）100%股权（截至评估基准日，北京慧通 100% 股权的评估价值为-6,889.14 万元)以及 7,822.13 万元债权以 2,000 万元一揽子 转让给中创永强（北京）科技有限公司（以下简称"中创永强"）。本次转让完成 后，公司不再持有北京慧通及其子公司股权，北京慧通及其子公司不再纳入公司 合并报表范围。具体内容详见公司于 2025 年 4 月 19 日在巨潮资讯网披露的相关 公告。 二、交易进展 截至本公告出具之日，公司已收到第一期股权及债权转让对价款，标的资产 已过户，后期公司将及时督促交易对方按交易协议支付剩余股权及债权转让对价 款。公司将持续跟进本次交易的进展情况，及时履行信息披露义务。敬请广大投 资者理性投资，注意风险。 证券代 ...

Group 1 - The core point of the announcement is that the company plans to absorb and merge its wholly-owned subsidiary, Zhengzhou Kuai Chu Catering Management Co., Ltd., to optimize its business structure and improve operational efficiency [1][2]. - The merger will result in the cancellation of Zhengzhou Kuai Chu's independent legal status, with all assets, liabilities, and personnel being inherited by the company [1][2]. - The merger does not constitute a related party transaction and does not require shareholder approval, as it falls within the company's internal restructuring efforts [1][2]. Group 2 - Zhengzhou Kuai Chu has total assets of 102.76 million yuan and a net asset of -6.64 million yuan as of December 31, 2024, with no revenue generated in 2024 [2]. - The merger is expected to enhance resource integration and organizational structure without significantly impacting the company's normal operations or financial status [2][3]. - The company's board of directors has authorized the general manager to handle all necessary procedures related to the merger [1][2].